133 related articles for article (PubMed ID: 6329205)
1. Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences.
Couvineau A; Rouyer-Fessard C; Fournier A; St Pierre S; Pipkorn R; Laburthe M
Biochem Biophys Res Commun; 1984 Jun; 121(2):493-8. PubMed ID: 6329205
[TBL] [Abstract][Full Text] [Related]
2. Binding of vasoactive intestinal peptide and its stimulation of adenylate cyclase through two classes of receptors in rat liver membranes. Effects of 12 secretin analogues and 2 secretin fragments.
Waelbroeck M; Robberecht P; De Neef P; Chatelain P; Christophe J
Biochim Biophys Acta; 1981 Nov; 678(1):83-90. PubMed ID: 6272875
[TBL] [Abstract][Full Text] [Related]
3. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
[TBL] [Abstract][Full Text] [Related]
4. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.
Laburthe M; Amiranoff B; Boige N; Rouyer-Fessard C; Tatemoto K; Moroder L
FEBS Lett; 1983 Aug; 159(1-2):89-92. PubMed ID: 6307754
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
Juarranz MG; De Neef P; Robberecht P
Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
[TBL] [Abstract][Full Text] [Related]
6. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
Laburthe M; Couvineau A; Rouyer-Fessard C
Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
[TBL] [Abstract][Full Text] [Related]
7. Effects of PHI on vasoactive intestinal peptide receptors and adenylate cyclase activity in lung membranes. A comparison in man, rat, mouse and guinea pig.
Robberecht P; Tatemoto K; Chatelain P; Waelbroeck M; Delhaye M; Taton G; De Neef P; Camus JC; Heuse D; Christophe J
Regul Pept; 1982 Oct; 4(5):241-50. PubMed ID: 6294750
[TBL] [Abstract][Full Text] [Related]
8. Interaction of thymic peptide thymosin alpha 1 with vasoactive intestinal peptide (VIP) receptors.
Calvo JR; Goberna R; Guerrero JM
Biosci Rep; 1986 Aug; 6(8):727-33. PubMed ID: 3028522
[TBL] [Abstract][Full Text] [Related]
9. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
[TBL] [Abstract][Full Text] [Related]
10. Interaction of synthetic N- and C-terminal fragments of helodermin with rat liver VIP receptors.
Robberecht P; Yanaihara N; Yanaihara C; De Neef P; Camus JC; Vandermeers A; Vandermeers-Piret MC; Christophe J
Peptides; 1986; 7 Suppl 1():79-82. PubMed ID: 3018706
[TBL] [Abstract][Full Text] [Related]
11. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
[TBL] [Abstract][Full Text] [Related]
12. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
13. Effector mechanisms of peptides of the VIP family.
Christophe J; Svoboda M; Lambert M; Waelbroeck M; Winand J; Dehaye JP; Vandermeers-Piret MC; Vandermeers A; Robberecht P
Peptides; 1986; 7 Suppl 1():101-7. PubMed ID: 3018687
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
Rodríguez-Pena MS; Guijarro LG; Prieto JC
Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
[TBL] [Abstract][Full Text] [Related]
15. Interaction of vasoactive intestinal peptide with a cell line (HeLa) derived from human carcinoma of the cervix: binding to specific sites and stimulation of adenylate cyclase.
Prieto JC; Guerrero JM; de Miguel C; Goberna R
Mol Cell Biochem; 1981 Jul; 37(3):167-76. PubMed ID: 6268963
[TBL] [Abstract][Full Text] [Related]
16. Specific labelling by [125I]helodermin of high-affinity VIP receptors in rat liver membranes.
Robberecht P; Waelbroeck M; de Neef P; Camus JC; Vandermeers A; Vandermeers-Piret MC; Christophe J
FEBS Lett; 1984 Jun; 172(1):55-8. PubMed ID: 6329822
[TBL] [Abstract][Full Text] [Related]
17. Cerebral vascular adenylate cyclase: evidence for coupling to receptors for vasoactive intestinal peptide and parathyroid hormone.
Huang M; Rorstad OP
J Neurochem; 1984 Sep; 43(3):849-56. PubMed ID: 6086840
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide receptors in pancreas and liver. Structure-function relationship.
Christophe J; Svoboda M; Waelbroeck M; Winand J; Robberecht P
Ann N Y Acad Sci; 1988; 527():238-56. PubMed ID: 2839079
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
[TBL] [Abstract][Full Text] [Related]
20. The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.
Wulff B; Møller Knudsen S; Adelhorst K; Fahrenkrug J
FEBS Lett; 1997 Aug; 413(3):405-8. PubMed ID: 9303545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
